Clinical trials located in

Göttingen

Göttingen city is located in Germany. Currently, 9 clinical trials are being conducted in this city.

Göttingen, located in Lower Saxony, Germany, is renowned for its prestigious Georg-August University, founded in 1737. This vibrant academic hub has been a focal point for over 40 Nobel laureates, underlining its significant contribution to science and literature. The city’s historical charm is encapsulated in its well-preserved medieval architecture, including the Old Town Hall and the 14th-century St. Jacob’s Church. Göttingen also celebrates a unique tradition with the Gänseliesel fountain, where newly minted PhD graduates kiss the statue of a goose girl, marking it as a symbol of academic achievement.

  • CT-EU-00116695

    Study on combining two drugs – Fianlimab and Cemiplimab in patients with previously untreated melanoma

    This study examines two drugs, fianlimab and cemiplimab, given together for the treatment of melanoma. The main goal is to see how effective this drug combination is in treating melanoma compared with pembrolizumab, which is already approved for the treatment of melanoma in adults. The study will also look at whether there are any differences in the effects of these experimental drugs in adolescents and adults.

    Scientists also want to learn about other key issues: what side effects may occur from taking these experimental drugs, how much of the drugs enter the bloodstream over time, and whether the body produces antibodies to the drugs that could make them less effective or cause side effects. They will also check whether taking medications improves patients’ quality of life. Fianlimab and cemiplimab will be administered by intravenous infusion, and pembrolizumab will be administered by intravenous infusion.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Study of the drug combination mRNA-4157/V940 and Pembrolizumab in the treatment of melanoma

    The aim of this clinical trial is to test whether a new drug called mRNA-4157/V940 in combination with pembrolizumab can help prevent the recurrence of melanoma in people who have already had it. Currently, mRNA-4157/V940 is what is called “individualized neoantigen therapy,” which means it is a therapy created specifically for each patient based on their cancer cells. Doctors give this drug along with pembrolizumab, a drug that helps the immune system fight cancer cells.

    The main goal of this study is to determine whether taking V940 and pembrolizumab together is more effective in preventing melanoma recurrence than taking pembrolizumab alone. Researchers will closely monitor how long it takes for the cancer to return or spread. The study will last for approximately 74 months.

    BelgiumDenmarkFranceGermanyGreeceItalyPolandPortugalSpainSwedenUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Exploring safe treatment options for Multiple Sclerosis

    This study is investigating the effects of Ofatumumab and Siponimod in comparison to a medication called Fingolimod in young patients with Multiple Sclerosis. The study comprises two parts: the Core Part, which spans two years, and the Extension Part, which can last up to five years. In the Core Part, participants are assigned one of the three medications to compare their respective effects. Qualified participants from the Core Part have the option to continue their treatment in the Extension Part. Progress is monitored by assessing the number of disease exacerbations per year, observing changes in scans that detect alterations related to the disease, and conducting blood tests. These blood tests are instrumental in measuring the levels of the medications in the body and ensuring that they do not have adverse effects.

    AustriaBelgiumFranceGermanyItalyPolandPortugalRomaniaSlovakiaSpain
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Evaluating pelacarsen as a treatment for heart patients undergoing lipoprotein reduction therapy

    This is a study exploring a drug therapy called pelacarsen and its impact on heart patients undergoing lipoprotein apheresis. Lipoprotein apheresis is a treatment used to lower high levels of cholesterol in the blood that hasn’t responded to lifestyle changes or standard medications. This trial investigates whether giving patients pelacarsen reduces their need for this invasive and time-consuming process. The study takes place in Germany and aims to recruit 60 patients with hyperlipoproteinemia(a), a condition where there’s a high level of lipoproteins in the blood, and who have existing heart disease. The plan is to see if pelacarsen can make these regular treatments less necessary. It’s a randomized trial, meaning participants in the study will be assigned randomly to two groups: one receiving the pelacarsen treatment and the other a placebo. The study intends to determine whether the drug helps reduce lipoprotein levels more effectively than the placebo. The main measures of success will be the reduction of needed lipoprotein apheresis sessions and any changes in the patient’s lipid profile. The study will also monitor changes in the patient’s quality of life.

    Germany

See more clinical trials in other cities in Germany:

.